2021/04/20
The Institute of Medical Science, The University of Tokyo
´ºÓêÖ±²¥app School of Medicine
Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion
Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization
Sapporo Medical University
? We have developed a nucleic acid drug candidate consisting of a highly sequence-specific chimeric siRNA targeting the PRDM14 gene, a transcription factor overexpressed in breast and pancreatic cancer, and a Y-shaped block co-polymer (YBC) that delivers nucleic acids to lesions.
? Intravenous administration of this nucleic acid drug candidate to animal models of breast and pancreatic cancer suppressed tumor growth. In distant metastasis models, a reduction in metastatic foci and prolonged survival were also observed.
? The results of this study were published online in the International Journal of Cancer on April 13, 2021. Based on these results, an investigator-initiated clinical trial of this nucleic acid drug candidate was initiated in September 2020.
For the full press release, please see below.